Check Claims Before You Publish

Evidence summary (selected, fully-cited papers showing scope & impact)

• Plasma SEPT9 as CRC screening marker (high translational impact): Patai is a co-author on the 2012 PLoS ONE validation of methylated SEPT9 in plasma for colorectal cancer screening, a frequently-cited translational biomarker paper demonstrating sensitivity/specificity advantages over conventional tests (reported n, assay performance, and context are in the paper) — this signals competence in liquid-biopsy epigenetic assays and translational biomarker validation.
  mSEPT9 plasma CRC screening (PLoS ONE 2012)
• Clinical guideline authorship (microscopic colitis, multi-author, high visibility): Patai appears as a contributing co-author on the 2020 United European Gastroenterology guideline on microscopic colitis — guideline contributions indicate involvement in clinical consensus and guideline drafting which have different epistemic weight (consensus + evidence grading) than primary research but increase clinical influence.
  Microscopic colitis guideline (UEG/EMCG 2020)
• Interdisciplinary breadth — example in AMR surveillance: Patai is a co-author on a 2020 Scientific Reports paper detecting antimicrobial resistance genes in raw milk, illustrating an ability to participate in genomic/metagenomic investigations beyond oncology and gastroenterology and collaborate across veterinary/public-health contexts.
  AMR genes in raw milk (Scientific Reports 2020)

Interpretation & scientific-strength critique

Evidence-based takeaways:

1. Publication volume and influence: The OpenAlex snapshot lists ~141 works, ~2,613 cited-by events and h-index ~26 (author-level metrics indicate sustained productivity and moderate citation impact typical of active clinical-translational investigators). The author’s output clusters in translational biomarker studies and clinical gastroenterology guidelines (supported by the cited representative papers above).
2. Strengths: Reproducible translational focus (liquid biopsy DNA methylation biomarkers), participation in multi-center clinical guideline work, and interdisciplinary co-authorships (molecular diagnostics, gastroenterology, AMR genomics). High citation counts on several collaborative papers indicate influence in applied clinical/translational spaces.
3. Limitations / blind spots: Many high-cited outputs are multi-author clinical/translational studies — attribution of conceptual novelty vs. collaborative execution is harder to resolve without contributorship statements; mechanistic basic-science contributions appear less prominent than translational/clinical work; reproducibility/independent external validations of some biomarker claims should be checked paper-by-paper (biomarker space often shows publication and positive-result biases).
4. Methodological rigor: The representative studies use appropriate designs for their aims (assay validation, guideline evidence summaries, metagenomic surveys). Rigor assessment should be done per-paper (sample sizes, blinding in diagnostic studies, pre-registration, independent validation cohorts); translational biomarker claims require independent prospective validation before clinical adoption.

Where conclusions would change

What would reduce confidence in the positive assessment above:

• Discovery that several biomarker papers lack independent validation cohorts or have methodological issues (small n, no blinding, overfitting) would lower translational impact.
• Evidence of undisclosed conflicts of interest or data irregularities in high-citation works would weaken trustworthiness.

Suggested next steps to evaluate/reproduce author claims

1. Conduct paper-by-paper methodological checklists (sample size, cohort composition, blinding, statistical corrections, code/data availability).
2. Search for independent prospective validations of key biomarkers (e.g., SEPT9) and harmonize effect estimates via meta-analysis.
3. Request contributorship/author contribution statements where available to disambiguate role (PI vs collaborator vs lab staff).

Representative high-impact works cited above used as concrete anchors for topical and impact claims; for any specific paper you want a deep methodological critique (risk-of-bias, result-reproducibility, raw-data extraction and graphing), click the Run AI Scientist Analysis button below to launch an agent that will fetch full texts and perform automated evidence extraction and reproducibility checks.